Relapse Timing Is Associated With Distinct Evolutionary Dynamics in Diffuse Large B-Cell Lymphoma
Laura K. Hilton(BC Cancer Agency), David W. Scott(BC Cancer Agency), Alina S. Gerrie(University of British Columbia), Pedro Farinha, Manuela Cruz(Simon Fraser University), Jeffrey W. Craig(Rockefeller University), Kerry J. Savage(Spinal Cord Injury BC), Laurie H. Sehn(BC Cancer Agency), Susana Ben‐Neriah(Apple (Israel)), Brett Collinge(Spinal Cord Injury BC), Robert Kridel(University of Toronto), Diego Villa(BC Cancer Agency), Christian Steidl(University of British Columbia), Graham W. Slack(BC Cancer Agency), Michael Crump(University of Toronto), Ciara L. Freeman(Moffitt Cancer Center), Annette E. Hay(Queen's University), Andrew Roth(Canadian Centre for Applied Research in Cancer Control), Henry S. Ngu(Spinal Cord Injury BC), Marco A. Marra(University of British Columbia), Ryan D. Morin(Simon Fraser University), Jasper Wong, Aly Karsan(University of British Columbia), John Kuruvilla(Princess Margaret Cancer Centre), Merrill Boyle, Kostiantyn Dreval(Simon Fraser University), Barbara Meissner, Kevin Song(Vancouver General Hospital), Christopher Rushton(Simon Fraser University), Judith Anula Rodrigo(University of British Columbia), Lois E. Shepherd(Ontario Institute for Cancer Research)
Cited by 50
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
|New England Journal of Medicine|2003|2.1k
The NIH Roadmap Epigenomics Mapping Consortium
|Nature Biotechnology|2010|2k